Market Overview

UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy

Related AMAG
Events for the Week of Nov. 17-21, 2014
Benzinga's Top Upgrades

Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation.

In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we believe the Company is undervalued at these levels. Our valuation method which renders a 12 month PT of $15.00 (Table on next page) does give some credit to the potential impact of label expansion but takes a conservative approach to valuing cash (we use cash by YE-2013) and uses conservative revenue multiples (2.0x)."

Ladenburg Thalmann has established a $15 price target on AMAG Pharmaceuticals, which is currently trading up $0.62 from yesterday's $12.54 closing price.

Latest Ratings for AMAG

DateFirmActionFromTo
Sep 2014JefferiesUpgradesHoldBuy
Sep 2014FBR CapitalUpgradesMarket PerformOutperform
Aug 2014FBR CapitalInitiates Coverage onMarket Perform

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: Ladenburg ThalmannAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (AMAG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional